Lining up allogeneic CAR Ts at ASH: Data Byte

Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year. 

The past year has seen a growing number of clinical readouts for off-the-shelf allogeneic chimeric antigen receptor (CAR) T cells, which stand to cut the cost, variability and lag time of autologous CAR T cell therapies individually manufactured for each patient...